Industry Strength Score
34/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
NFL BIOSCIENCES SA (ALNFL.PA) Stock Price & Overview
EPA:ALNFL • FR0014003XT0
Current stock price
1.042 EUR
0 (-0.38%)
Last:
The current stock price of ALNFL.PA is 1.042 EUR. Today ALNFL.PA is down by -0.38%. In the past month the price decreased by -1.33%. In the past year, price decreased by -38.99%.
ALNFL.PA Key Statistics
52-Week Range0.851 - 1.846
Current ALNFL.PA stock price positioned within its 52-week range.
1-Month Range0.99 - 1.136
Current ALNFL.PA stock price positioned within its 1-month range.
- Market Cap
- 13.202M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.36
- Dividend Yield
- N/A
ALNFL.PA Stock Performance
Today
-0.38%
1 Week
-0.76%
1 Month
-1.33%
3 Months
-18.72%
Longer-term
6 Months -8.44%
1 Year -38.99%
2 Years -43.37%
3 Years -62.18%
5 Years N/A
10 Years N/A
ALNFL.PA Stock Chart
ALNFL.PA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ALNFL.PA. When comparing the yearly performance of all stocks, ALNFL.PA is a bad performer in the overall market: 94.53% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
ALNFL.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALNFL.PA. ALNFL.PA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ALNFL.PA Earnings
Next Earnings DateN/A
Last Earnings DateN/A
PeriodQ2 / 2022
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
ALNFL.PA Forecast & Estimates
11 analysts have analysed ALNFL.PA and the average price target is 2.99 EUR. This implies a price increase of 187.14% is expected in the next year compared to the current price of 1.042.
Analysts
Analysts81.82
Price Target2.99 (186.95%)
EPS Next Y-93.75%
Revenue Next YearN/A
ALNFL.PA Financial Highlights
Over the last trailing twelve months ALNFL.PA reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS increased by 54.35% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-1.83M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.64% | ||
| ROE | -84.25% | ||
| Debt/Equity | 0.01 |
Chartmill High Growth Momentum
EPS Q2Q%-423.53%
Sales Q2Q%N/A
EPS 1Y (TTM)54.35%
Revenue 1Y (TTM)N/A
ALNFL.PA Ownership
Ownership
Inst Owners0.08%
Shares12.67M
Float10.42M
Ins Owners17.79%
Short Float %N/A
Short RatioN/A
ALNFL.PA Industry Overview
ALNFL.PA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 52 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
78/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
19%
Outperformed 19% of sub-industries
3 Month Rank
20%
Outperformed 20% of sub-industries
6 Month Rank
35%
Outperformed 35% of sub-industries
Industry Fundamentals & Breadth
- Members
- 52
- New Highs
- 1.9%
- New Lows
- 11.5%
- Average ROE
- 26.7%
- Average Profit Margin
- 29.7%
- Average Operating Margin
- 25.9%
- Average P/E
- 37.8
- Average Fwd P/E
- 29.9
- Average Debt/Equity
- 0.0
ALNFL.PA Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.32 | 40.797B | ||
| 1AE | ARGENX SE | 28.29 | 40.784B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.748B | ||
| ABVX | ABIVAX SA | N/A | 7.414B | ||
| 2X1 | ABIVAX SA | N/A | 7.402B | ||
| GXE | GALAPAGOS NV | N/A | 1.583B | ||
| GLPG | GALAPAGOS NV | N/A | 1.58B | ||
| NANO | NANOBIOTIX | N/A | 1.367B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1B | ||
| PHARM | PHARMING GROUP NV | 46.68 | 997.578M | ||
| PHGN | PHARMING GROUP NV | 46.42 | 992.281M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 954.74M | ||
| IVA | INVENTIVA SA | N/A | 873.421M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALNFL.PA
Company Profile
NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. The company is headquartered in Castelnau-Le-Lez, Occitanie and currently employs 4 full-time employees. The company went IPO on 2021-07-05. The firm's products help cure addictions through an approach based on botanical pharmaceutical agents. The company develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. The firm applies scientific approach to other drug candidate with an initial focus targeting the growing addiction to cannabis.
Company Info
IPO: 2021-07-05
NFL BIOSCIENCES SA
199 rue Helene Boucher
Castelnau-le-Lez OCCITANIE FR
Employees: 5
Phone: 33411937667
NFL BIOSCIENCES SA / ALNFL.PA FAQ
Can you describe the business of NFL BIOSCIENCES SA?
NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. The company is headquartered in Castelnau-Le-Lez, Occitanie and currently employs 4 full-time employees. The company went IPO on 2021-07-05. The firm's products help cure addictions through an approach based on botanical pharmaceutical agents. The company develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. The firm applies scientific approach to other drug candidate with an initial focus targeting the growing addiction to cannabis.
What is the stock price of NFL BIOSCIENCES SA today?
The current stock price of ALNFL.PA is 1.042 EUR. The price decreased by -0.38% in the last trading session.
Does NFL BIOSCIENCES SA pay dividends?
ALNFL.PA does not pay a dividend.
How is the ChartMill rating for NFL BIOSCIENCES SA?
ALNFL.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is ALNFL.PA stock listed?
ALNFL.PA stock is listed on the Euronext Paris exchange.
What is the Price/Earnings (PE) ratio of NFL BIOSCIENCES SA (ALNFL.PA)?
NFL BIOSCIENCES SA (ALNFL.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.36).
Is NFL BIOSCIENCES SA (ALNFL.PA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALNFL.PA.